Intravenous thrombolysis before thrombectomy in acute ischemic stroke: a dual centre retrospective cohort study.
Islam El MalkyMahmoud AbdelhafizHazem Mo AbdelkhalekPublished in: Scientific reports (2022)
First pass effect (FPE) is a successful recanalization (mTICI ≥ 2b) after the first trial of thrombectomy. It is associated with good functional outcomes. Few studies discussed the effect of BT (bridging therapy: combined I.V. thrombolysis and mechanical thrombectomy) on FPE and clinical outcomes. In our study, we would like to report the effect of MT with or without preceding IVT on FPE and the functional outcome of AIS (Acute Ischemic Stroke) of anterior circulation in real practice. A dual-center retrospective cohort study enrolled 201 patients with AIS of anterior circulation and was divided into a bridging therapy (BT) group of 150 patients who received alteplase preceding thrombectomy, and a direct mechanical thrombectomy (dMT) group of 51 patients. Comparisons between both groups regarding the clinical and radiological outcome. Early better clinical outcome (mRS ≤ 2) at day seven with BT group (39.3%) rather than dMT (23.5%) with P value = 0.044. No significant differences as regard puncture to revascularization time, successful revascularization (mTICI) ≥ 2b and FPE between both groups (P value: 0.328, 0.538, and 0.708, respectively). No differences as regards hemorrhagic transformation, mortality rate, and 90-day favorable outcome between both groups (P value 0.091, 0.089, and 0.192, respectively). BT might have better early outcome than dMT but no difference as regards 90-day favorable outcomes, mortality, sICH, FPE, recanalization rate and procedure time. It might be reasonable to go directly to mechanical thrombectomy without IVT for AIS with large vessel occlusion.
Keyphrases
- acute ischemic stroke
- end stage renal disease
- cardiovascular events
- ejection fraction
- primary care
- middle cerebral artery
- healthcare
- risk factors
- newly diagnosed
- coronary artery bypass grafting
- clinical trial
- randomized controlled trial
- study protocol
- type diabetes
- peritoneal dialysis
- pulmonary embolism
- phase iii
- stem cells
- cardiovascular disease
- low dose
- endovascular treatment
- patient reported outcomes
- acute coronary syndrome
- mesenchymal stem cells
- minimally invasive
- skeletal muscle
- cell therapy
- quality improvement
- phase ii
- weight loss